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Introduction: C-X-C motif chemokine 10 (CXCL10) is a chemokine that plays a critical role in the infiltration of T
cells in autoimmune diseases and is reported to be expressed in muscle tissue of polymyositis. To determine the
therapeutic efficacy of CXCL10 blockade, we investigated the role of CXCL10 and the effect of anti-CXCL10 antibody
treatment in C protein-induced myositis (CIM), an animal model of polymyositis.
Methods: CIM was induced with human skeletal muscle C protein fragment in female C57BL/6 mice.
Immunohistochemistry of CXCL10 and C-X-C motif chemokine receptor 3 (CXCR3) and measurement of serum
CXCL10 were performed. Cell surface markers and interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α)
in CIM lymph node cells was investigated by flow cytometry. Mice with CIM were treated with anti-CXCL10
antibody or control antibody (anti-RVG1) and the inflammation in muscle tissue was assessed.
Results: Immunohistochemistry showed increased expression of CXCL10 and CXCR3 in the inflammatory lesions of
muscle in CIM. Especially, CD8+ T cells invading myofiber expressed CXCR3. Serum level of CXCL10 was increased in CIM
compared to the level in normal mice (normal mouse, 14.3 ± 5.3 pg/ml vs. CIM, 368.5 ± 135.6 pg/ml, P < 0.001). CXCR3
positivity in CD8+ T cells was increased compared to that of CD4+ T cells in the lymph node cells of CIM (CXCR3+
among CD8+ T cell, 65.9 ± 2.1% vs. CXCR3+ among CD4+ T cell, 23.5 ± 4.7%, P <0.001). Moreover, IFN-γ+ cells were
increased among CXCR3+CD8+ T cells compared to CXCR3–CD8+ T cells (CXCR3+CD8+ T cell, 28.0 ± 4.2% vs. CXCR3−CD8+
T cell, 9.5 ± 1.5%, P= 0.016). Migration of lymph node cells was increased in response to CXCL10 (chemotactic index was
1.91 ± 0.45). CIM mice treated with anti-CXCL10 antibody showed a lower inflammation score in muscles than those with
anti-RVG1 (median, anti-CXCL10 treatment group, 0.625 vs. anti-RVG1 treatment group, 1.25, P= 0.007).
Conclusions: CXCL10/CXCR3 expression was increased in the inflammation of CIM model and its blockade suppressed
inflammation in muscle.Introduction
Chemokines are 8- to 10-kDa proteins with 20 to 70%
amino acid sequence homology and produce chemotac-
tic activity in various cells, especially immune cells [1].
To date, approximately 50 different chemokines and
at least 20 different receptors have been identified [2].* Correspondence: ysong@snu.ac.kr
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reproduction in any medium, provided the orAmong them, C-X-C motif chemokine 10 (CXCL10;
also known as interferon-γ inducible protein-10, IP-10)
is a chemokine that potentially plays a role in the immu-
nopathogenesis of autoimmune disease such as rheuma-
toid arthritis, systemic lupus erythematosus, systemic
sclerosis, and idiopathic inflammatory myopathy (IIM)
[3-6]. It can be secreted by various cell types, such as,
monocytes, neutrophils, endothelial cells, keratinocytes,
fibroblasts, mesenchymal cells, dendritic cells, thyro-
cytes, cardiac cells, and astrocytes in diverse conditions
[7-9]. CXCL10 binds to its receptor CXC chemokine
receptor 3 (CXCR3), and regulates immune responses
by activation and recruitment of immune cells. CXCR3. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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face chemotactic receptor for C-X-C motif chemokine 9
(CXCL9; also known as monokine induced by interferon-
γ, MIG), CXCL10/IP-10, and C-X-C motif chemokine 11
(CXCL11; also known as interferon-inducible T cell α
chemoattractant, I-TAC), and has been suggested to play
an important role in lymphocyte trafficking, with preferen-
tially activated T cells [10]. Originally it was cloned from
T cells [11], but now it is clear that CXCR3 is expressed
on activated T cells, natural killer cells, monocytes,
dendritic cells, endothelial cells, and microglia [12-14].
These CXCR3+ cells can produce IFN-γ, which can induce
CXCL10 in turn. This crosstalk between immune cells
and resident cells may potentially activate the immune
system [15]. Previous reports suggested that chemokines
not only play an important role in lymphocyte recruitment
to inflammatory sites but also participate in T cell activa-
tion [16]. Especially, CXCL10 is implicated in autoimmune
pathogenesis through the initiation and maintenance of T
helper 1 (Th1) response [17].
IIMs are rare autoimmune diseases characterized by
proximal muscle weakness, elevated muscle enzymes, ab-
normal electromyographic findings, and inflammation or
vasculopathy in muscle tissue. IIMs are composed of many
kinds of diseases with idiopathic muscle inflammation and
include dermatomyositis, polymyositis, and sporadic inclu-
sion body myositis [18]. In polymyositis and inclusion
body myositis, non-necrotic muscle fibers are actively in-
vaded by autoaggressive macrophages and cytotoxic T cells
[18,19]. Despite recent advances in immunosuppression,
the treatment of IIM is not satisfactory. Although many
kinds of treatment including high-dose corticosteroid, in-
travenous immunoglobulin, azathioprine, cyclophospha-
mide or other immunosuppressant are available, some
patients do not respond to these treatments, especially,
when they have lung involvement [19,20].
Chemokines are also known to play an essential role in
sustaining the inflammation associated with IIM. In previ-
ous reports on IIMs, CXCL10 was abundantly expressed
on macrophages and T cells in polymyositis, inclusion
body myositis and dermatomyositis whereas CXCL9 and
CXCL11 were not altered compared to the control [6,21].
Strong CXCR3 expression has also been observed in the
majority of T cells in both polymyositis and dermatomyo-
sitis [6,21]. The above data suggest that the CXCL10/
CXCR3 interaction in particular may be a potential thera-
peutic target in IIM.
In an animal model of human polymyositis, C protein-
induced myositis (CIM), muscle damage is caused by
CD8+ T cell [22], which is similar to the mechanism of
damage in human polymyositis [23]. The purpose of this
study was to determine the therapeutic efficacy of anti-
CXCL10 antibody in the CIM model. First, the expression
of CXCL10 and CXCR3 in C-protein induced myositismice was investigated. Second, the functional aspect of
CXCR3-positive cells was studied, and last, the change in
muscle inflammation was evaluated after administration
of the anti-CXCL10 antibody.
Methods
C-protein-induced myositis model
C57BL/6 mice were purchased from OrientBio (Sungnam,
Korea). Female mice, ages 8 to 10 weeks, were immunized
intradermally with 200 μg of the C-protein fragments
emulsified in complete Freund’s adjuvant (CFA) contain-
ing 100 μg of heat-killedMycobacterium butyricum (Difco,
Franklin Lakes, NJ, USA) [22]. The immunogens were
injected at multiple sites of the back and foot pads, and
250 ng of pertussis toxin (PT) (Sigma-Aldrich, St Louis,
MO, USA) diluted with 0.03% Triton X was injected in-
traperitoneally at the same time. CIM mice were treated
with anti-CXCL10 antibody or anti-RVG1 (mouse anti-
rotavirus IgG1) antibody (n=17 per group). These anti-
bodies were obtained from mouse ascites after intraperito-
neal injection of hybridoma cells producing monoclonal
anti-CXCL10 or anti-RVG1 antibody as described previ-
ously [24]. Another 17 CIM mice were observed without
any treatment. Mice were immunized with C-protein at
day 0 and treated by injecting monoclonal antibody
200 μg in 100 μL PBS intraperitoneally every other day
from day 8 till day 20. Three weeks after induction, mice
were sacrificed and sera, spleens and proximal muscles
(hamstring and quadriceps) of both hind legs were har-
vested. Hematoxylin and eosin-stained 10-μm sections of
the proximal muscles were examined histologically for the
presence of mononuclear cell infiltration and necrosis of
muscle fibers. The histologic severity of inflammation
in each muscle block was graded as follows: grade 1 = in-
volvement of a single muscle fiber; grade 2 = a lesion
involving 2 to 5 muscle fibers; grade 3 = a lesion involving
6 to 15 muscle fibers; grade 4 = a lesion involving 16 to 30
muscle fibers; grade 5 = a lesion involving 31 to 100
muscle fibers; and grade 6 = a lesion involving >100
muscle fibers. When multiple lesions with the same grade
were found in a single muscle section, 0.5 of a point was
added to the grade. Histologic grading was modified from
the article by Sugihara et al. [22]. All experiments were
done under specific pathogen-free conditions. The experi-
ment was approved by the Institutional Animal Care and
Use Committee in Seoul National University Hospital.
Immunohistochemistry
Immunohistochemical staining for the presence of CXCL9,
CXCL10, CXCL11 or CXCR3 was performed according to
the manufacturer’s protocol based on the conventional
streptavidin-biotin-peroxidase method. Representative sec-
tions of 3-μm thickness of paraffin-embedded muscle tissue
were rehydrated after deparaffinization by xylene. Antigen
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with citrate buffer. Then, the sections were immersed in
3% H2O2 for 10 minutes to inhibit endogenous peroxidase
activity and washed three times by PBS over the course of
5 minutes. Then, the sections were incubated with various
primary antibodies. The primary antibodies were as fol-
lows: anti-CXCL9, anti-CXCL10, anti-CXCL11 (Abcam,
Cambridge, UK; 1:200) or anti-CXCR3 (Invitrogen, Carlsbad,
CA, USA; 1:200). Antigen retrieval was performed by boil-
ing in citrate buffer: 3,3-diaminobenzidine tetrahydrochlo-
ride (DAB) was used as a chromogen. Counterstaining
with Meyer’s hematoxylin stain followed.
Cryostat-frozen sections (8 μm) were also used for detec-
tion of CXCR3. The sections fixed in cold acetone were
stained overnight at 4°C with mouse anti-mouse CD4
(Abcam; 1:100), rat anti-mouse CD8a (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA; 1:100), rat anti-mouse F4/80
(AbD Serotec, Kidlington, UK; 1:100), rabbit anti-mouse
CXCR3 (Invitrogen; 1:100) with blocking reagents. A sec-
ond layer of Alexa Fluor 555-conjugated anti-rabbit, Alexa
Fluor 488-conjugated anti-mouse, and Alexa Fluor 647-
conjugated anti-rat antibody (all antibodies were purchased
from Molecular Probes, Eugene, OR, USA; 1:100) were
used as secondary antibodies, respectively. All sections
were washed and incubated for an additional 5 minutes
with 4′-6-diamidino-2-phenylindole (DAPI, Molecular
Probes) for counterstaining. For negative control, pri-
mary antibodies were omitted. The bound antibodies
were visualized using LSM510 META confocal laser mi-
croscopy (Carl Zeiss, Jena, Germany).
Flow cytometry
Splenocytes of normal mice and CIM mice, and inguinal
lymph node cells of CIM mice were harvested. The sple-
nocytes were purified by Ficoll-gradient methods. The
cells were enumerated, and 5 × 105 cells were incubated
with Fc Block™ (1 μg/mL; BD Bioscience, San Jose, CA,
USA). Staining of the cells was performed with the follow-
ing antibodies: peridinin chlorophyll(PerCP)-labeled anti-
mouse CD3 (BD Bioscience), phycoerytherin(PE)-labeled
anti-mouse CXCR3, allophycocyanin(APC)-labeled anti-
mouse CXCR3, fluorescein isothiocyanate(FITC)-labeled
anti-mouse CD4, FITC-labeled anti-mouse CD8, PE-Cy5-
labeled anti-mouse F4/80, APC-labeled anti-mouse B220,
PE-labeled anti-mouse interferon-gamma (IFN-γ), or PE-
labeled anti-mouse TNF-α. All antibodies were purchased
from eBioscience (San Diego, CA, USA).
For intracellular cytokine staining, 5 × 105 lymph node
cells were plated in Roswell Park Memorial Institute
medium (RPMI) 1640 supplemented with 10% fetal calf
serum, 100 U penicillin/mL and 100 μg/mL streptomycin
(Gibco, Carlsbad, CA, USA). Cultures were incubated with
phorbol 12-myristate 13-acetate (PMA; 100 ng/mL; Sigma-
Aldrich) plus ionomycin (500 ng/mL; Sigma-Aldrich) in thepresence of brefeldin A (10 μg/mL; BD Pharmingen, San
Diego, CA, USA) for 4 hours at 37°C. After stimulation,
cells were permeabilized with BD Cytofix/Cytoperm™ so-
lution according to the manufacturer’s instructions (BD
Pharmingen), stained with antibodies, and fixed with 1%
paraformaldehyde. Flow cytometry was performed using a
FACSCanto (Becton Dickinson, Franklin Lakes, NJ, USA),
and results were analyzed using FlowJo software (TreeStar
Inc. Ashland, OR, USA).Enzyme-linked immunosorbent assay (ELISA) of CXCL10
Concentrations of CXCL10 in mouse sera were mea-
sured with sandwich ELISA kits (MCX100, R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions.Migration assay
Inguinal lymph node cells of CIM were harvested and the
migration of lymph node cells was evaluated using a Co-
star Transwell system (24-well, 5-μm pore size membrane;
Corning Costar, Cambridge, MA, USA). Briefly, a total of
5 × 105 cells were added to the top chamber with 0.1 mL
serum-free RPMI 1640. The bottom chamber was filled
with 0.6 mL serum-free RPMI 1640 with or without 200 ng/
mL recombinant mouse CXCL10 (R&D systems) [25]. The
chambers were incubated for 3 hours at 37°C. Then, the
transmigrating cells in the bottom well were counted in
nine randomly captured images. Each experiment was per-
formed in triplicate.Statistical analysis
All values are expressed as mean ± SD or median (mini-
mum (min), maximum (max)). As some variables were
not normally distributed, we used the t-test or paired t-test
to analyze parametric variables and the Kolmogorov-
Smirnov test, Mann-Whitney U-test, and Kruskal-Wallis
test to analyze non-parametric variables (SPSS software;
SPSS Inc). A P-value <0.05 was considered statistically
significant.Results
Presence of CXCL10 in the muscle and serum of CIM
To investigate whether CXCL10 is expressed in CIM, we
stained the muscle of CIM with anti-CXCL9, anti-CXCL10,
or anti-CXCL11 antibody. Immunohistochemistry showed
the positive staining of CXCL10 in the inflammatory lesion
of CIM. CXCL9 or CXCL11 was weakly stained (Figure 1A).
In addition, serum levels of CXCL10 were increased in
CIM compared to normal mice (normal mouse, 14.3 ±























Figure 1 Expression of CXCL10 in C-protein-induced myositis (CIM). (A) Immunohistochemistry of CXCL9, CXCL10 and CXCL11 in the muscle
of CIM (×400). In the inflammatory lesion of CIM, CXCL10 was strongly stained whereas CXCL9 or CXCL11 was weakly stained. (B) Serum level of
CXCL10 in normal mice and CIM mice. The level of CXCL10 was measured by ELISA in the sera of normal mice (n = 10) and CIM mice (n = 10) at
3 weeks after induction. The serum level of CIM was more elevated in CIM than in normal mice (normal mouse, 14.3 ± 5.3 pg/ml versus CIM,
368.5 ± 135.6 pg/ml, P <0.001). The horizontal lines indicate the mean.
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node of CIM
CXCR3 positive cells were also scattered in the lymph
nodes and inflammatory lesions of muscle tissue (Figure 2A).
Moreover, CXCR3-positive cells invading myofiber ex-
pressed CD8 but not CD4 (Figure 2B). F4/80+ macrophages
at the focus of the inflammation, not within myofiber, also
expressed CXCR3 (Figure 2C). The proportion of CXCR3
positivity in immune cells of regional lymph nodes was
measured by flow cytometry. Normal mice did not show
discrete lymphadenopathy, thus, lymph node cells could
not be obtained. Using flow cytometry, the CXCR3+ cell
was found to be 15.7 ± 3.7% among CIM lymph node
cells. CXCR3+ cells were composed of CD3+CD8+ T cells
(51.5 ± 3.0%), CD3+CD8− T cells (31.4 ± 2.9%), B220+ cells
(12.1 ± 6.0%) and F4/80+ cells (4.3 ± 2.6%, Figure 2D). The
proportion of CXCR3+ T cells among CD4+ T cells was
23.5 ± 4.7% while the proportion of CXCR3+ T cells among
CD8+ Tcells was 65.9 ± 2.1% (n = 6, P <0.001, paired t-test).
IFN-γ expression increased in CXCR3 + CD8+ T cells of
CIM regional lymph node
The intracellular cytokines IFN-γ and TNF-α in CD8+ T
cells were analyzed by flow cytometry. CXCR3 positivitywas associated with IFN-γ positivity (CXCR3+CD8+ T
cell, 28.0 ± 4.2% versus CXCR3-CD8+ T Cell, 9.5 ± 1.5%,
P = 0.016, paired t-test). TNF-α+ cells were also present.
However, TNF-α was not associated with CXCR3 posi-
tivity in the lymph node cells of CIM (CXCR3+CD8+ T
cell, 34.7 ± 4.3% vs. CXCR3-CD8+ T cell, 38.0 ± 1.5%,
P = 0.362, paired t-test, Figure 3).
Migration of CIM lymph node cells was increased by
CXCL10
Inguinal lymph node cells of CIM were stimulated with
CXCL10 (200 ng/ml) or without CXCL10 in the migration
assay. The degree of migration was calculated as a chemo-
tactic index (number of migrated cells in the presence of
CXCL10/number of migrated cells in the absence of
CXCL10). Increased migration of the cells in the presence
of CXCL10 was observed (chemotactic index was 1.91 ±
0.45, n = 5, P = 0.011 versus control, Kolmogorov-Smirnov
test).
Therapeutic effect of neutralizing anti-CXCL10 antibody
in CIM
The CIM mice were treated with intraperitoneal injection
of monoclonal anti-CXCL10 (200 μg/100 μL) or anti-RVG1




Figure 2 Expression of CXCR3 in the lymph node and muscle of C-protein-induced myositis (CIM). (A) Immunohistochemistry of CIM
muscle tissue and lymph node. CXCR3 was expressed in some cells of the lymph node cells (left, ×200) and inflammatory lesion in the muscle
of CIM (right, ×400). (B) Immunostaining of cells invading myofiber in muscle of CIM. Differential interference contrast (DIC) showed myofiber
and invasive cells in the middle of myofiber. The CD8 was co-stained with CXCR3 whereas CD4 was not (×1,000). (C) Immunostaining of
inflammation in muscle of CIM showed F4/80 co-stained with CXCR3 (×1,000). (D) CXCR3-positive immune cells in CIM lymph node. CIM lymph
node cells were analyzed by flow cytometry. CXCR3-positive cells were gated from lymph node cells. CXCR3-positive cells were analyzed by
cell-specific markers (CD3 for T cells; B220 for B cells; F4/80 for macrophages).
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day 8 to day 20. Three weeks after induction, muscle in-
flammation was compared between treatment groups by
the histologic score. The group treated with monoclonal
anti-CXCL10 antibody showed significant improvement
of muscle inflammation (n = 17 per group, median (min,
max), anti-CXCL10 treatment, 0.625 (0, 2.00) versus anti-
RVG1 treatment, 1.25 (0.5, 4.25) versus no treatment, 1.75
(0.875, 3.875), P <0.001, Kruskal-Wallis test). The group
treated with anti-CXCL10 was improved compared with the
group treated with anti-RVG1 (P = 0.007, Mann-Whitney
U-test) or the group which did not receive any treat-
ment (P <0.001, Mann-Whitney U-test, Figure 4). In
addition, serum levels of CXCL10 were not differentbetween the group treated with anti-CXCL10 and the
group treated with anti-RVG1 (n = 10, anti-CXCL10 treat-
ment, 370.51 ± 123.39 pg/ml versus anti-RVG1 treatment,
381.12 ± 111.74, pg/mL, P = 0.843, t-test).
Discussion
We investigated the role of the CXCL10/CXCR3 axis using
a murine model of polymyositis based on a previous study
on the chemokine profile of human IIM [6]. CXCL10 and
CXCR3 were expressed in the inflammatory lesion in the
CIM muscle tissue. Moreover, CXCR3+CD8+ T cells infil-
trated myofiber. Treatment with anti-CXCL10 ameliorated
muscle inflammation in CIM mice, which suggested that
the CXCL10/CXCR3 interaction seems to play a crucial
Figure 3 The IFN-γ and TNF-α positivity by CXCR3 expression in CD8+ T cells. Lymph node cells of C protein-induced myositis (CIM) were
stimulated with phorbol 12-myristate 13-acetate, ionomycin and brefeldin A for 4 hours. CD3+CD8+ cells were gated (left) and analyzed
according to the presence of CXCR3 and effector molecules. Representative figure of three experiments.
Figure 4 Therapeutic effects of anti-CXCL10 or control antibody treatment in C-protein-induced myositis (CIM). After inducing CIM, mice
were treated with anti-CXCL10 antibody or control antibody (anti-RVG1) or were not treated (n = 17 per group). The group treated with anti-CXCL10
showed a lower inflammation score in muscles than those with anti-RVG1 or no treatment. No treatment: no treatment group, anti-CXCL10: anti-CXCL10
treatment group, anti-RVG1: anti-RVG1 treatment group. anti-RVG1, mouse anti-rotavirus IgG1.
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However, the serum level of CXCL10 was not different be-
tween anti-CXCL10 treatment group and anti-RVG1 treat-
ment group despite efficacy of treatment. It is well known
that treatment of anti-TNF agent can increase serum
level of TNF-α. Serum TNF-α level in patients with vari-
ous inflammatory diseases such as rheumatoid arthritis,
ankylosing spondylitis or TNF receptor-associated periodic
syndrome was known to be increased after treatment with
soluble receptor [26] or anti-TNF antibody [27] irrespect-
ive of efficacy. The cause of elevation can be attributed to
increased half-life of TNF-α [28] or upregulated expression
of TNF-α [29]. Presence of anti-CXCL10 could also inter-
fere with the CXCL10 assay [30].
Several animal models of myositis have been introduced
[22,31-33]. CIM used in this study was established as a
simple murine model of polymyositis. A single injection
into mice of recombinant human muscle protein induced
severe and clinically significant inflammation of the skel-
etal muscles. Previous studies on the CIM demonstrated
that several types of immune cells could be involved. Mac-
rophages and CD4+ T cells are also abundant in the
muscle inflammation [22]. The depletion of CD8+ T cells
or CD4+ T cells showed protective effects in CIM [22].
Thus, CD4+ T cells as well as CD8+ T cells might partici-
pate in the pathogenesis. However, CD8+ T cells were
enriched in the endomysial site, the site of the muscle in-
jury, and expressed perforins preferentially at the endomy-
sial site. Class I major histocompatibility complex (MHC)
expression was upregulated in muscles with severe inflam-
mation in mice with CIM [22]. Moreover, removal of class
I MHC significantly suppressed myositis and the adoptive
transfer model suggested that the CD8 T cell-induced
muscle injuries were significantly more severe than the
CD4 T cell-induced muscle injuries [23]. Especially when
evaluating the necrotic muscle area representing the area
with direct muscle injury, CD8+ T cells were dominant. In
this regard, the new CIM model provides a clear contrast
to the previous experimental autoimmune myositis model
in which the injury appears to be driven by CD4+ T cells.
The finding that CD8+ cytotoxic T lymphocytes primarily
damage the muscle fibers in CIM confirmed that CIM is
the mouse myositis model most analogous to human poly-
myositis. The present study showed that CXCR3 was
expressed in CD8+ T cells more than in CD4+ T cells in
regional lymph node and moreover, muscle-invasive CD8+
T cells expressed CXCR3.
In this study, CXCR3+CD8+ T cells showed more fre-
quent IFN-γ positivity in the inguinal lymph node. IFN-γ
is important in amplification of inflammation with coord-
ination with CXCR3 [34]. IFN-γ mediates the induction of
CXCL10 and its binding to CXCR3 recruits CXCR3+ cells.
These CXCR3+ T cells, in turn, produce IFN-γ. This IFN-
γ-CXCR3-dependent inflammatory loop potentially maynot only enhance the generation of cytotoxic T cells [35]
but also enhance the increased effector response [15].
Moreover, TNF-α+ T cells were abundant in the inguinal
lymph node cells in this study. TNF-α+ cells have been
found to be present in the muscle tissue of IIMs [36].
TNF-α or the TNF-α-related pathway are probably im-
portant in inducing CXCL10. Recently, TNF family mem-
bers, B-cell activating factor and a proliferation-inducing
ligand were significantly elevated in the sera of patients
with IIMs and correlated positively with CXCL10 [37].
Vitamin D receptor agonist targeting downstream of
TNF-α pathway decreased the CXCL10 secretion from
human fetal skeletal muscle cells [38]. Thus the TNF-α/
TNF-α-related pathway can play an important role in the
inflammatory mechanisms of IIMs.
As mentioned earlier, CXCR3 has at least three li-
gands, those are CXCL9, CXCL10, and CXCL11, and the
role of its ligands in various disease models is not the
same. In some inflammatory models, the requirement of
one CXCR3 ligand dominates, and its deficiency cannot
be compensated for by the presence of the other ligands.
Although all three ligands are induced by dengue virus
infection, CXCL9 and CXCL11 could not compensate
for the absence of CXCL10 in Cxcl10−/−mice [39]. In a
model that uses acute lymphocytic choriomeningitis
virus infection of transgenic mice that express the glyco-
protein of lymphocytic choriomeningitis virus in the
cells of the islets of Langerhans, all CXCR3 ligands were
upregulated in the pancreas. However, disease develop-
ment was abrogated only in mice treated with CXCL10
neutralizing antibodies, whereas CXCL9 neutralizing
antibodies had no effect on disease development [40]. In
contrast, Cxcr3- and Cxcl9-deficient, but not Cxcl10-de-
ficient MRL/lpr mice were protected from autoimmune
lupus-like inflammation of the kidney [41]. Among vari-
ous chemokines, CXCL10 is implicated in autoimmune
pathogenesis through the initiation and maintenance of
Th1 response. It appears to be related with the patho-
genesis of autoimmune disease and not associated with
general inflammatory conditions [17]. Not only circulat-
ing levels of CXCL10 but also the tissue expression was
increased in various autoimmune diseases including
rheumatoid arthritis, systemic lupus erythematosus, sys-
temic sclerosis, type I diabetes mellitus and autoimmune
thyroid disease, [4,5,42-44]. From these studies, other cy-
tokines including CXCL9 or CXCL11 may have a role in
the pathogenesis of CIM. However, we chose CXCL10 in
this study because its expression is abundant in the
muscle tissue of CIM in this study and polymyositis un-
like CXCL9 or CXCL11 [6].
The source of CXCL10 is not clear based on this study.
The previous study of the immunolocalization of CXCL10
showed expression in the inflammatory lesion and vessel,
but not in muscle fiber [6]. Immunohistochemistry of
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staining in the infiltrating cell. However, it might be
expressed in inflamed muscle tissue. Recently, primary
human muscle cell was found to secrete CXCL10 after
stimulation with TNF-α or IFN-γ [45]. Those results sug-
gested the active role of muscle cells in the immune re-
sponse. Further study focusing on the interaction between
muscle cell and immune cells such as CD8+ T cells, CD4+
T cells, or macrophage may be useful.
IIM is known to be a Th1-driven autoimmune process
characterized by significant inflammatory cell infiltrates in
muscle and other tissue, resulting in muscle injury [46].
About 25% of IIM patients cannot tolerate or are refractory
to conventional therapies [47] and there are no defined
guidelines for treatment of refractory myositis [48]. There-
fore, the development of new therapeutic agents is neces-
sary. In addition to polymyositis, the CXCL10/CXCR3 axis
was also reported to be involved in inclusion body myositis
and dermatomyositis. CXCL10 is abundantly expressed in
macrophages and T cells surrounding and invading non
necrotic muscle fibers in inclusion body myositis [49].
CXCL10 expression on T cells in the perimysial infiltrates
of dermatomyositis and CXCR3 expression on the majority
of T cells in dermatomyositis were also reported [21].
Juvenile-type dermatomyositis also showed high expression
of CXCL10 in muscle tissue [50] and the expression of
CXCL10 and recruitment of CXCR3+ T cells were detected
in the skin lesions of dermatomyositis [51].
In clinical aspects, the development of a therapeutic
agent against CXCL10/CXCR3 in IIM is plausible. As
mentioned in the introduction, the studies demonstrated
that the expression of CXCL10 and CXCR3 was increased
in the collagen-induced arthritis model, and neutralizing
anti-CXCL10 antibodies ameliorated disease manifestation
in these models [52,53]. Moreover, CXCL10 and CXCR3
expression is also increased in the synovial membrane of
rheumatoid arthritis patients [3,10]. Thus, a clinical trial of
blocking antibody against CXCL10 showed a promising
outcome [30]. Taking the results of this study into consid-
eration in parallel with the studies on rheumatoid arthritis,
the CXCL10/CXCR3 pathway may be a candidate as a
therapeutic target in human IIMs.
Conclusion
Our study reveals that expression of CXCL10 and its recep-
tor, CXCR3 is increased in the inflammation site and lymph
node cells of the CIM model. Moreover, myofiber-invasive
CD8+ T cells express CXCR3. CXCL10 blockade with
monoclonal antibody suppresses inflammation in muscle,
which suggests CXCL10 inhibition could be used as a
potential therapeutic strategy for treatment of myositis.
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